key: cord-1050481-n88s3vji
authors: Pacifico, A.; d’Arino, A.; Pigatto, P. D. M.; Malagoli, P.; Young Dermatologists Italian Network,; Damiani, G.
title: COVID‐19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast
date: 2021-06-09
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14723
sha: 056fed642afe220d18d69910a0b78ecb4336c9db
doc_id: 1050481
cord_uid: n88s3vji

Although COVID-19 vaccination is warmly suggested for psoriatic patients by several dermatological societies worldwide, only a recently published Italian case-series has sustained a safe and effective role of the vaccine in this patients' subset. Remarkably, vaccines information highlights that limited data are present for immunosuppressed patients and the vaccination should be performed in agreement with the vaccinator.

experienced flares of both his PsO and PsA during asymptomatic COVID-19, which resolved spontaneously 10 days after COVID-19 remission. Six months after this infection, he received both doses of the Pfizer mRNABNT162b2 vaccine without experiencing any PsO flare. Patient 2, a 76-year-old man with PsO, had been taking apremilast since 2017 with a stable residual Psoriasis Area Severity Index (PASI) of 3. After the first dose of the Astra-Zeneca-Oxford vaccine AZD1222 he experienced fever (38.5°C) and myalgia for 3 days, whereas the second dose was not complicated by any adverse effects (AEs). On both occasions he did not experience any PsO flare. Patient 3 was a 36-year-old woman with plaque PsO (PASI 3) and concurrent pustular PsO (Palmoplantar Psoriasis Area and Severity Index 2.3), who had been stably treated with apremilast and narrowband UVB for 3 years. She received the Pfizer mRNABNT162b2 vaccine without any AEs or PsO flare.

All four patients developed IgG antibodies to the SARS-CoV-2 S1 receptor binding domain, suggesting that apremilast does not interfere with the acquisition of SARS-CoV-2 immunity. Furthermore, none of the COVID-19 vaccines, both mRNA-based and viral vector-based, did not trigger PsO or PsA flares in any of these three patients treated with apremilast. Interestingly, real-life data have also highlighted the potential protective effect against SARS-CoV-2 in this patient subset, 5,6 while at the same time warning about the possible apremilast-related gastrointestinal and taste AEs, which may be misinterpreted as suggestive of COVID-19. [7] [8] [9] 

Analytical methods for determination of apremilast from bulk, dosage form and biological fluids: a critical review

World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology

COVID-19 vaccination and psoriatic patients under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers

COVID-19 knowledge prevents biologics discontinuation: data from an Italian multicenter survey during RED-ZONE declaration

Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond

Severe bitter taste associated with apremilast

Management of common side effects of apremilast

We thank the patients for their written informed consent to publication of their case details.